Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose

Summary

Hypothesis: The supplementation of Ergocalciferol (Vitamin D2) to those with Vitamin D deficiency in the Chronic Kidney Disease population requiring recombinant human erythropoietin for the treatment of anemia related to kidney disease will reduce the dose of erythropoietin required to maintain a nonanemic state.

Timeline

Start

2010-08

Primary completion

2011-09

Completion

2011-09

Outcome

Outcome not reported

Stopped (Enrollment): “Strong enrollment efforts resulted in few eligible subjects and high screen failures due to CKD patients with higher vitamin D levels than anticipated.”

Drugs

Indications